Deletions of DNA in cancer and their possible uses for therapy

Bioessays. 2023 Jul;45(7):e2300051. doi: 10.1002/bies.202300051. Epub 2023 May 11.

Abstract

Despite advances in treatments over the last decades, a uniformly reliable and free of side effects therapy of human cancers remains to be achieved. During chromosome replication, a premature halt of two converging DNA replication forks would cause incomplete replication and a cytotoxic chromosome nondisjunction during mitosis. In contrast to normal cells, most cancer cells bear numerous DNA deletions. A homozygous deletion permanently marks a cell and its descendants. Here, we propose an approach to cancer therapy in which a pair of sequence-specific roadblocks is placed solely at two cancer-confined deletion sites that are located ahead of two converging replication forks. We describe this method, termed "replication blocks specific for deletions" (RBSD), and another deletions-based approach as well. RBSD can be expanded by placing pairs of replication roadblocks on several different chromosomes. The resulting simultaneous nondisjunctions of these chromosomes in cancer cells would further increase the cancer-specific toxicity of RBSD.

Keywords: cancer therapy; deletions in cancer; replication roadblocks.

MeSH terms

  • DNA Replication / genetics
  • DNA* / genetics
  • Homozygote
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Sequence Deletion

Substances

  • DNA